[PDF] Top 20 The challenge of comorbidity in clinical trials for multiple sclerosis

... Sclerosis (ECTRIMS), during the conduct of this work, and personal con- sulting fees from Bayer HealthCare, Biogen Idec, Coronado Biosciences Inc., the Cleveland Clinic Foundation, Eli Lilly and Company, from EMD ... See full document

... Canada, Multiple Sclerosis Scientific Foundation, and Rx & D Health Research Foundation; and has conducted clinical trials funded by ...of Multiple Sclerosis ...National ... See full document

... Foundation, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Rx&D Health Research Foundation, and has conducted clinical trials funded by ... See full document

... rehabilitation trials is desperately ...in multiple sclerosis (MS) was ...placebo-controlled trials of sufficient power, especially with the levels of funding typically available for these ... See full document

... health challenge and a complex disorder characterised by a cluster of interconnected factors which lead to an increased risk of cardiovascular disease (CVD) and dia- betes mellitus type 2 ...of comorbidity ... See full document

... III trials using fingolimod have recently been published (Table ...fewer multiple relapses, and longer overall time to first relapse in comparison to the active control group and had a higher percentage of ... See full document

... of clinical trials in MS, use of more sensitive and pow- erful outcome measures to maximize the ability of detecting treatment effects is becoming increasingly ...placebo-controlled clinical ... See full document

... MS clinical trial data, Wang et ...the clinical situation [15]. In real clinical studies, the concerned events might occur rarely, several events might occur simultaneously, or several events might ... See full document

... relapsing–remitting multiple sclerosis ...III trials by reducing the annualized relapse rate, preventing multiple sclerosis (MS) lesion accumulation on magnetic resonance imaging, and ... See full document

... Within clinical trials, patients were retreated with a subsequent 3-day course of alemtuzumab if they experienced 1 protocol-defined relapse or 2 new or enlarging brain or spinal cord ...In ... See full document

... relapsing multiple sclerosis ...modest clinical benefits and are commonly not tolerated due to side ...controlled trials to have an exceptional effect on preventing relapses, decreasing the ... See full document

... of multiple sclerosis is important not only to exclude other disorders and give prognosis but also for epidemiological studies and entering patients in multicentre clinical trials for ...the ... See full document

... of clinical disability, and MRI- related ...both trials included bradycardia, macular edema, nasopha- ryngitis, dyspnea, headaches, diarrhea, and ... See full document

... However, clinical trials in MS patients have lingered, as the above-mentioned epigenetic processes have not yet been established as biomarkers for the development and severity of the ...and trials in ... See full document

... In trials of disease-modifying MS medications that have included visual outcomes, treatment benefit on visual func- tion has been ...harm. Clinical experience in terms of numbers of patients treated and ... See full document

... of clinical phenotypes of MS patients included in the study, as well as age at initiation of MTX therapy, have to be considered possible factors determining a modification of the observed effects when comparing ... See full document

... the CHMP expressed concerns regarding a higher occur- rence of cancers after long-term exposure to the compound in animal studies and noted that a similar long-term cancer risk could not be sufficiently excluded in ... See full document

... in multiple sclerosis (MS), including cortical reorganization, have been actively studied in recent ...of clinical and basic studies in the field of MS by two leading Russian ...centers. ... See full document

... Abstract: Multiple sclerosis is a frequent neurologic disease, which causes sensory impairment, fatigue, cognitive deficits, imbalance, loss of mobility, spasticity, and bladder and bowel ...controlled ... See full document

... changes are transient abnormalities in the blood-brain barrier that are thought to be re- sponsible for contrast enhancement in MR im- aging. Contrast-enhanced MR images are more sensitive in showing lesion activity than ... See full document